Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
Promising Results for BAER-101 in Preclinical Study of Absence Epilepsy
Avenue Therapeutics Makes Breakthrough in Absence Epilepsy Treatment, Despite Financial Setback
FDA Greenlights Avenue Therapeutics* Phase 3 Protocol for IV Tramadol in Landmark Agreement
Avenue Therapeutics* Milestone Trial Advances Potential Treatment for Kennedy*s Disease
Avenue Therapeutics Inc Sets New Standard for Seizure Treatment with BAER-101 Breakthrough
Avenue Therapeutics Inc Boosts Growth with Surging Working Expenditures in Q3 2023
Avenue Therapeutics Inc Reports Substantial Operating Deficit of $-6.429 Million in Q1 2023
Business outlays were building up at the ATXI in the most recent fiscal period